Trial reportBlood advances2026
Efficacy and safety of selinexor combined with VRD in newly diagnosed multiple myeloma with EMD: a phase 2 trial.
Trial report in Blood advances, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05900882 (An Open Label, Single Arm, Multi-Center Exploratory Study to Evaluate the Efficacy and Safety of SVRd for the Treatment of Newly Diagnosed Multiple Myeloma Patients Presenting With Extramedullary Disease.), which is not on this map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
An Open Label, Single Arm, Multi-Center Exploratory Study to Evaluate the Efficacy and Safety of SVRd for the Treatment of Newly Diagnosed Multiple Myeloma Patients Presenting With Extramedullary Disease.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
abstractExtramedullary disease (EMD) at diagnosis confers a poor prognosis in newly diagnosed multiple myeloma (NDMM). This multicenter, open-label, single-arm, phase 2, investigator-initiated trial evaluated selinexor combined with bortezomib, lenalidomide, and dexamethasone (SVRD) in NDMM with EMD. Between 17 October 2022 and 27 November 2025, 30 patients were enrolled; 29 treated patients formed the modified intention-to-treat (mITT) and safety populations (median age, 60 years). Induction comprised four 28-day SVRD cycles with protocol-specified consolidation/maintenance and optional autologous stem cell transplantation (ASCT). The primary end point was best overall response rate (ORR) during induction according to International Myeloma Working Group criteria. Patients without a postbaseline assessment were imputed as nonresponders. In the mITT cohort, the ORR was 89.7% (stringent complete response [CR], 58.6%; CR, 3.4%; very good partial response, 10.3%; partial response, 17.2%). Imaging documented EMD regression in 89.7% of patients (complete resolution, 79.3%; partial resolution, 10.3%). The 12-month progression-free survival and overall survival rates were 87.9% and 96.3%, respectively (medians not reached; median follow-up, 18 months). High-risk cytogenetics were present in 31.0% of patients, and 27.6% met the ultra-high-risk (double-hit) criteria. Grade ≥3 treatment-emergent adverse events occurred in 37.3% of patients, most commonly thrombocytopenia (24.1%), neutropenia (6.9%), and pneumonia (10.3%); no treatment-related deaths occurred. SVRD produced deep hematologic responses and high EMD clearance with manageable toxicity, thereby enabling ASCT in 51.7% of participants. These findings support SVRD as a rational frontline option for EMD-positive NDMM and justify randomized studies to confirm durability and to benchmark it against contemporary quadruplets and cellular therapies. This trial was registered at www.ClinicalTrials.gov as NCT05900882.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.